Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Blood (2024) 144 (16): 1747–1751.

https://doi.org/10.1182/blood.2024024351

Published: 2024

Includes: Supplemental data

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Blood (2024) 144 (4): 445–456.

https://doi.org/10.1182/blood.2023022273

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical decision-making and treatment of myelodysplastic syndromes

Eva S. Hellström-Lindberg, Nicolaus Kröger

Blood (2023) 142 (26): 2268–2281.

https://doi.org/10.1182/blood.2023020079

Published: 2023

Journal Articles

How I treat transplant-eligible patients with myelofibrosis

Nicolaus Kröger, Christine Wolschke, Nico Gagelmann

Blood (2023) 142 (20): 1683–1696.

https://doi.org/10.1182/blood.2023021218

Published: 2023

Journal Articles

ATG or Post-Transplant Cyclophosphamide to Prevent Gvhd in Matched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Nicolaus Kröger, Matthias Stelljes, Tobias Gedde-Dahl, Igor Wolfgang Blau, Thomas Schroeder, Urpu Salmenniemi, Aleksandr Kulagin, Sr., Regis Peffault De Latour, Stephan Mielke, Jürgen Finke, Ivan Sergeevich Moiseev, Helene Schoemans, Christian Koenecke, Zinaida Peric

Blood (2023) 142 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2023-180504

Published: 2023

Journal Articles

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Blood (2023) 142 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2023-185945

Published: 2023

Journal Articles

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

Blood (2023) 142 (Supplement 1): 704.

https://doi.org/10.1182/blood-2023-184783

Published: 2023

Journal Articles

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 896.

https://doi.org/10.1182/blood-2023-179489

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gulbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Matthias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Sergeevich Moiseev, Helene Schoemans, Christian Koenecke, Zinaida Peric

Blood (2023) 142 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2023-179837

Published: 2023

Journal Articles

Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) Versus Conventional Anti-Graft Versus Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 237.

https://doi.org/10.1182/blood-2023-174020

Published: 2023

Journal Articles

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Radwan Massoud, Evgeny Klyuchnikov, Ameya Shrinivas Kunte, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2023-188745

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 898.

https://doi.org/10.1182/blood-2023-178287

Published: 2023

Journal Articles

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Nour Moukalled, Myriam Labopin, Jurjen Versluis, Gerard Socié, Didier Blaise, Urpu Salmenniemi, Alessandro Rambaldi, Tobias Gedde-Dahl, Eleni Tholouli, Nicolaus Kröger, Jean-Henri Bourhis, Peter A. Von Dem Borne, Etienne Daguindau, Édouard Forcade, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2023-185434

Published: 2023

Journal Articles

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2023-174609

Published: 2023

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Blood (2023) 142 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2023-174599

Published: 2023

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2023-185685

Published: 2023

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Clinical decision-making and treatment of myelodysplastic syndromes

How I treat transplant-eligible patients with myelofibrosis

ATG or Post-Transplant Cyclophosphamide to Prevent Gvhd in Matched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only